(Date:8/18/2008)...- Oramed,Pharmaceuticals, I...developer,of oral delivery systems, announced toda... Assess the Safety, Pharmacokinetics (PK) and,Phar...s in Healthy,Subjects," has been chosen for presen...European Association for the Study of Diabetes (EA...
(Date:8/17/2008)...nhua-- Pharmaxis,(ASX: PXS;...tal Phase 3,clinical trial of Bronchitol for the t...t., The first efficacy data from the trial is exp...9. The trial commenced its dosing phase in,April 2... subjects in June,2008 and closed today with 325 s...
(Date:8/14/2008)...BiTE) showing clinical benefit in cancer,patients;...gnize and attack canc...tCall/ -- Micromet, Inc.,(Nasdaq: MITI ), a bioph...,antibodies for the treatment of cancer, inflammat...cation of a Phase 1 clinical study(1) on its,BiTE(...
(Date:8/13/2008)...irstCall/ -- As biotechnology,pharmaceutical and ...l,trials beyond their own borders to other parts o...h America, complicated regulatory environments,cha...ing to an analysis by,Aon Corporation (NYSE: AOC ...ose companies a visual representation of the compl...
Breaking Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4Healthcare M 26A Activity on the Rise 9649 1Healthcare M 26A Activity on the Rise 9649 2Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 1Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 2Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 3New Poll 3A Only 16 25 of Californians Support Mandatory Purchase of Private Health Insurance 3B 71 25 Behind Regulation of Premium Increases 9641 1New Poll 3A Only 16 25 of Californians Support Mandatory Purchase of Private Health Insurance 3B 71 25 Behind Regulation of Premium Increases 9641 2Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 1Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 2...ss.--(BUSINESS WIRE)--Mar 14, 2007 - ArQule, Inc.,...ociety of,Clinical Oncology (ASCO) has accepted fo... 197 (A Phase 1 Dose Escalation Study of,ARQ 197, ...ients,with Metastatic Solid Tumors) at the 43rd AS...s presentation will describe findings,from a Phase...
...lough Announces Presentation Of Phase II Trial Res...t The 2007 Annual,Meeting Of The American College ...6, 2007 /PRNewswire-FirstCall/ --,Schering-Plough ...ase II trial of its novel oral thrombin receptor a...e 2007 annual Scientific Sessions,of the of Cardio...
Other Medicine Technology:ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 2ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 3ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 4Media Advisory: ACC Updated Schedule 2(Date:8/20/2008)...usetts General Hospital (MGH) investigators have f...em cell appeared to protect gastrointestinal tissu...ir report published in the journal Stem Cells , t...icine report that mesenchymal stem cells (MSCs), k...allowed the regeneration of the gastrointestinal l...
(Date:8/20/2008)...NGTON, Aug. 20 /PRNewswire-USNewswire/ -- Yesterda... admitted to Huron Hospital after,suffering an ane...Ohio. At,the present time Rep. Tubbs Jones, condit...are available., Tuesday,s condition followed a fu...ming forum on electoral reform, scheduled for Sept...
(Date:8/20/2008)... Micro(R) PUMP and ELLEgirl.com Send Four Girls to...Summer, LOS ANGELES, Aug. 20 /PRNewswire/ -- Reti...eenage Web site ELLEgirl.com to send four contest,...Camp in Santa Monica,California. With the new sch...mpower girls to become successful women by helping...
(Date:8/20/2008)...IEGO, Aug. 20 /PRNewswire/ --You,re late for work,...r car won,t start. How do you deal with,the rising...ash out in,frustration, how you deal with anger af...r children and even your career., As hard as we m...push,our buttons. While feeling anger isn,t a bad ...
Breaking Medicine News(10 mins):Health News:Bone marrow stem cells may help control inflammatory bowel disease 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 2Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 3Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 4Health News:Special Summer Camp Helps Girls Recognize Inner and Outer Beauty 5Health News:Taming Your Temper: Learning to Turn Down the Heat 2... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
Medicine Products: